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D
irected traffi  cking is how the cell 
patterns itself, and Ira Mellman 
has been a leader in efforts to un-
derstand this feat of self-organization. He 
started with the discovery, naming, and char-
acterization of endosomes (1), moved to 
study pathways (2), sorting determinants (3), 
and sorting adapters (4) 
in polarized epithelial 
cells, and has more re-
cently revealed how 
dendritic cells reorgan-
ize themselves to present 
antigens (5, 6). Now, 
however, he is ready for 
a new challenge. In 
April 2007, he started 
as Director of Research 
Oncology at Genentech 
in South San Francisco, 
CA. He joins Genentech’s other recent 
converts from academia such as Richard 
Scheller, Marc Tessier-Lavigne, Vishva 
Dixit, and Eric Brown. As Mellman rushed 
to get ready for the move, he discussed 
both his past work and future hopes.
TRAFFICKING
How did you connect ﬁ  rst with 
Zanvil Cohn and Ralph Steinman at 
Rockefeller and then with Ari Helenius 
at Yale?
In the late 1970s, Cohn and Steinman 
published a series of absolutely spectacular 
papers on endocytosis and membrane 
dynamics. So I went to learn cell biology, 
and was a bit horrifi  ed when I got there to 
fi  nd that they were really immunologists.
As for Yale, I was being recruited by 
George Palade, who proceeded to tell me 
that he had just hired Ari Helenius from 
EMBL in Heidelberg. Apparently, he had 
also told Ari that I was going. Neither of 
us had actually agreed to go, but we both 
decided, “Well, if this other guy’s going, I 
might as well also.” Finally, we met and 
realized that we’d kind of been snookered. 
I believe John Huston used much the same 
technique to get both Humphrey Bogart 
and Katharine Hepburn to star in “The 
African Queen.” 
But it worked out really for the best. 
We met several times and decided basi-
cally to merge our laboratories from the 
moment we arrived in 1981. We shared a 
lab, a desk, and a phone. Our kids basi-
cally grew up together, and science and 
family ruled our lives. It was a magical 
time in many ways.
Why trafﬁ  cking?
At the time I entered the field, it was 
exploding at the conceptual level. The 
idea was that, “Gee, this is really what 
controls overall cell organization.”
George had basically laid out for us 
what his generation had done: they had 
defi  ned all of the working components of 
the cell, all the organelles, and what must 
happen. Our responsibility was to fi  gure 
out the mechanisms by which all of this fi  ts 
together: what the pathways were; how 
membranes knew to form vesicles; and 
how those vesicles contained the right 
cargos that knew where to go. The entire 
fi  eld took that on as the charge, and for the 
next decade and a half this effort yielded 
one terrifi  c new principle after the next.
And dendritic cells?
In the early 1990s, Ari and I began to get a 
little squirrelly looking for more challenges 
rather than just continuing to beat up on 
endocytosis. We were getting the feeling 
that these efforts were becoming repetitive 
with less conceptual content. Many of our 
colleagues were starting to do the same 
things again and again, 
working incrementally 
on the same genes or 
their binding partners.
Around that time, 
we had adapted our 
technology for char-
acterizing endosomes 
to isolate antigen-
processing compart-
ments from B cells. 
Ralph’s response 
was, “Don’t waste 
your time with B 
cells; dendritic 
cells are much 
more important.” 
But there were 
no cell lines. 
Ralph actually 
sent us cells on 
the train from New York. All the shaking 
on Metro-North caused the cells to 
switch their organization and function 
overnight, which we noticed also hap-
pened after stimulating them with various 
immune agonists. There was an awful lot 
of cell biology involved in that, not the 
least of which involved some terrific 
alterations in membrane traffi  c. It also 
had an increasing relevance to under-
standing how immunity is generated and 
to human biology and disease.
How would you describe your current 
philosophy about biological research?
We’re at a bifurcation point. You can take 
problems into extraordinary molecular or 
even atomic-level detail, which is I think 
the natural course for most scientists. You 
grab onto a problem and you wring its 
neck until it yields all of its secrets. But for 
me, the true conceptual excitement is 
learning how to apply molecular informa-
tion to understand more complex, systems-
level phenomena. You have to follow the 
most profound and most exciting problems 
wherever they lead you regardless of the 
techniques, cell types, genes or systems 
New proteins in polarized cells travel from trans-Golgi to recycling 
endosomes before reaching the cell surface.
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Disease-related research requires a different kind of teamwork, says Ira Mellman. 
He hopes to ﬁ  nd that team at his new home at Genentech.
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involved. Pick your problem and go after 
it and don’t let your problem pick you.
Why the move to Genentech?
Applying reductionist approaches to 
solving complex problems in humans is 
extraordinarily diffi  cult 
to approach in academia. 
Academia does a great 
job with tissue culture 
cells or fl  ies or mice, but 
it doesn’t easily accom-
modate the types of 
broad-based interdisci-
plinary teams that you 
really need in order to organize experiments 
using human beings as a biological system.
I’ve been grappling with this problem 
at the Ludwig Institute and the Yale 
Comprehensive Cancer Center. But now 
people with exactly the same background 
as myself have offered me the possibility 
of coming and playing in a completely 
different sandbox.
Why does Genentech often recruit from 
academia rather than pharma?
They believe that drug discovery begins as 
a valid problem of basic science. If that’s 
the case, then you have to get the best scien-
tists, the people with the broadest under-
standing of fundamental aspects of biology 
and biomedicine, to manage the process.
The brilliance of Genentech is that it 
melds the rigor and deep commitment to 
fundamental science that one fi  nds from 
excellent people coming 
from the academic world 
with the discipline, insight, 
and creativity characteristic 
of the best of the biotech and 
pharmaceutical industry. 
These two groups come to-
gether with a terrifi  c amount 
of mutual respect.
In my view, Genentech 
has turned drug development 
into a scientifi  c problem of 
the fi  rst  order.  The  people 
who have moved there were 
all at the tops of their games 
career-wise; they certainly 
didn’t need to fi  nd jobs. They 
aren’t doing this for the 
money, yet they go.
What challenges come with a switch 
from an academic to biotech 
environment?
In academia, the basic process is cyclical. 
We develop a project, write a paper, get it 
published, get a grant, and turn the crank 
again. In biotech you still want to publish 
but that’s not the only end point. You want 
to get something into humans. So you 
have to have a high level of intellectual 
and scientifi  c discipline to keep yourself 
on message.
That’s going to be a challenge, but a 
really welcome challenge. After 25 years 
or more of doing science, I could say 
I’m getting a bit tired of turning the crank. 
It’s very satisfying, but it’s iterative. 
This new task is much more vectorial 
and linear.
In my case, another reason I went to 
Genentech is that my oldest son, Peter, 
has Crohn’s Disease. When he was crash-
ing with the disease and became unre-
sponsive to all the conventional therapies, 
they were basically considering removing 
his entire gastrointestinal tract. He lost 
half his body weight and was in continu-
ous pain.
Then they treated him with a mono-
clonal antibody to TNFα, a drug called 
Remicade (not a Genentech product, by 
the way). Within 36 hours, Peter and I 
were playing basketball in the front drive-
way, and it was a realization that hey, you 
know, this biotech stuff can really do it. 
This is a miracle.
Knowing something 
about this pathway, we 
established a company in 
New Haven called CGI 
Pharmaceuticals that target-
ed immune cells involved 
in this disease. Genentech 
ended up buying the rights 
to that particular agent. Now, 
I can help oversee the devel-
opment of that agent, which 
might eventually be used as 
a more effective mainte-
nance therapy for my own 
son. At the risk of sounding 
melodramatic, there can be 
nothing, absolutely nothing, 
that would be more satisfy-
ing to me as a scientist.
Genentech’s marketing of drugs such as 
TPA, growth hormone, and Avastin has 
sometimes been controversial. How 
does a for-proﬁ  t drug company ﬁ  t with 
your liberal family background, which 
emphasized social justice?
It’s worse: I come from a long line of 
socialists and labor organizers. Neverthe-
less, the only way to turn science into 
realistic, utilitarian products that can be 
used to benefi  t individuals and society is 
to make use of the capitalist system. I 
have come to grips with that.
Companies and people who run them 
are going to make money out of pharma-
ceuticals. And because money is involved, 
not everyone is going to, at all times, be 
scrupulously moral or honest. Having met 
a number of people at various levels at 
Genentech, however, I feel that the cur-
rent management and leadership structure 
is about as trustworthy as any group of 
individuals I’ve seen anywhere. They all 
seem to be liberal, open-minded people 
who are deeply concerned with the inter-
face between science and society, and 
indeed troubled by the fact that pricing 
structures can wind up creating drugs that 
are hugely expensive. They try very hard 
to mitigate that.
As a future Director of Research 
Oncology, what is your vision of human 
cancer research?
I have come to dislike the term “transla-
tional research.” It incorrectly evokes a 
process whereby basic discoveries made 
in the laboratory using mice can simply 
be translated to humans. In reality, this is 
rarely the case. What we need is clinical 
discovery research with a rigorous, re-
ductionist scientifi  c approach to human 
cancer using human patients as subjects. 
The only model for human cancer is 
human cancer.
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A switch in ubiquitination 
status sends MHC II (red) 
to the surface in mature 
dendritic cells (bottom).
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“The only 
model for 
human cancer 
is human 
cancer.”